Key result
Omalizumab triggers Takotsubo syndrome in a first reported adverse event case.
Why the study?
Although omalizumab has a high efficacy and excellent safety profile, rare adverse effects including allergic reactions and cardiovascular events have been described.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Clinicians should consider Takotsubo syndrome in omalizumab-treated patients with acute chest pain; first case extends monoclonal antibody associations but leaves causality open.
BACKGROUND: Omalizumab is a humanized monoclonal anti-immunoglobulin E antibody, approved for the treatment of spontaneous chronic urticaria, with high efficacy and an excellent safety profile. Although its adverse effects are rare, allergic reactions and cardiovascular events were previously described. CASE SUMMARY: The authors describe the case of a 75-year-old woman, followed at the outpatient dermatology clinic due to spontaneous chronic urticaria, treated with omalizumab 300 mg every 4 weeks. After the 11th administration of omalizumab, the patient developed an episode of thoracalgia associated with electro- and echocardiographic abnormalities. Coronary angiogram excluded coronary artery disease, and left ventriculography demonstrated mid-apical akinesia and basal hyperkinesia, consistent with the Takotsubo syndrome (TS). DISCUSSION: Takotsubo syndrome was already reported in association with other monoclonal antibodies. However, to our knowledge, this is the first case of TS following the administration of omalizumab.
No takes yet. Share an insight, caveat, or question.
Aguiar-Ricardo et al. (2019) conducted a case report in Spontaneous chronic urticaria (n=1). Omalizumab was evaluated on Development of Takotsubo syndrome. Omalizumab administration induced Takotsubo syndrome in a 75-year-old woman being treated for spontaneous chronic urticaria, marking the first reported case of this adverse event.
Synapse has enriched 10 related papers. Consider them for comparative context: